Clinical data | |
---|---|
Trade names | Elpida |
Other names | VM 1500; elpivirine |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C24H17BrCl2FN3O5S |
Molar mass | 629.28 g·mol−1 |
|
Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] [2] [3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A). [4] It was developed by the Russian company Viriom. [5]
In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs. [4] [6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir. [7]
Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation. [8] [9]
In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication. [5]
Clinical data | |
---|---|
Trade names | Elpida |
Other names | VM 1500; elpivirine |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
Chemical and physical data | |
Formula | C24H17BrCl2FN3O5S |
Molar mass | 629.28 g·mol−1 |
|
Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). [1] [2] [3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A). [4] It was developed by the Russian company Viriom. [5]
In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs. [4] [6] Currently, elsulfavirine is used in antiretroviral therapy regimens in the Russian Federation, which includes the combination elsulfavirine + lamivudine (or emtricitabine) + tenofovir. [7]
Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation. [8] [9]
In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication. [5]